Litcius/Paper detail

Repression of LKB1 by miR-17∼92 Sensitizes MYC-Dependent Lymphoma to Biguanide Treatment

Said Izreig, Alexandra Gariepy, Irem Kaymak, Hannah R. Bridges, Ariel O. Donayo, Gaëlle Bridon, Lisa M. DeCamp, Susan M. Kitchen-Goosen, Daina Avizonis, Ryan D. Sheldon, Rob C. Laister, Mark D. Minden, Nathalie A. Johnson, Thomas F. Duchaîne, Marc S. Rudoltz, Sanghee Yoo, Michaël Pollak, Kelsey S. Williams, Russell G. Jones

2020Cell Reports Medicine30 citationsDOIOpen Access PDF

Abstract

expression as a potential biomarker for biguanide sensitivity in malignancies.

Topics & Concepts

BiguanideAMPKGene silencingCancer researchPhenforminCancer cellChemistryProtein kinase ACell biologySignal transductionmicroRNABiologyKinaseCancerBiochemistryMetforminEndocrinologyGeneGeneticsDiabetes mellitusMetabolism, Diabetes, and CancerAutophagy in Disease and TherapyCancer-related Molecular Pathways
Repression of LKB1 by miR-17∼92 Sensitizes MYC-Dependent Lymphoma to Biguanide Treatment | Litcius